Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

IF 14.8 2区医学 Q1 ONCOLOGY Journal of the National Comprehensive Cancer Network Pub Date : 2024-05-01 DOI:10.6004/jnccn.2204.0023

Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm DeCamp, Aakash P Desai, Thomas J Dilling, Jonathan Dowell, Gregory A Durm, Scott Gettinger, Travis E Grotz, Matthew A Gubens, Aditya Juloori, Rudy P Lackner, Michael Lanuti, Jules Lin, Billy W Loo, Christine M Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C Mullikin, Thomas Ng, Dawn Owen, Dwight H Owen, Sandip P Patel, Tejas Patil, Patricio M Polanco, Jonathan Riess, Theresa A Shapiro, Aditi P Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C Yang, Edwin Yau, Kristina M Gregory, Lisa Hang

{"title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","authors":"Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm DeCamp, Aakash P Desai, Thomas J Dilling, Jonathan Dowell, Gregory A Durm, Scott Gettinger, Travis E Grotz, Matthew A Gubens, Aditya Juloori, Rudy P Lackner, Michael Lanuti, Jules Lin, Billy W Loo, Christine M Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C Mullikin, Thomas Ng, Dawn Owen, Dwight H Owen, Sandip P Patel, Tejas Patil, Patricio M Polanco, Jonathan Riess, Theresa A Shapiro, Aditi P Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C Yang, Edwin Yau, Kristina M Gregory, Lisa Hang","doi":"10.6004/jnccn.2204.0023","DOIUrl":null,"url":null,"abstract":"<p><p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":"22 4","pages":"249-274"},"PeriodicalIF":14.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2204.0023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非小细胞肺癌，4.2024 版。

非小细胞肺癌（NSCLC）NCCN 肿瘤学临床实践指南（NCCN 指南）为非小细胞肺癌患者的治疗提供了建议，包括诊断、原发疾病管理、复发监测和后续治疗。该小组根据 FDA 的最新批准和临床数据更新了推荐的靶向疗法列表。本节选自《NCCN NSCLC 指南》，重点介绍对具有可操作分子生物标记物的晚期或转移性 NSCLC 的治疗建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the National Comprehensive Cancer Network ONCOLOGY-

CiteScore

20.20

自引率

0.00%

发文量

388

审稿时长

4-8 weeks

期刊介绍： JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care. Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.